文献速递前列腺癌

试验组间治疗差异能否解释欧洲前列腺癌筛查随机研究中前列腺癌死亡率的降低

Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
PubMed 文献 · Eur Urol · 2019-03-28

该研究基于欧洲前列腺癌筛查随机研究(ERSPC)中14 136例前列腺癌患者(筛查组7310例,对照组6826例),采用多因素模型量化治疗差异对前列腺癌死亡率降低的贡献。结果显示,调整临床病理特征后,两组治疗分布差异仅为-3.3%至3.3%,远小于观察到的7.2%至10.1%的差异;治疗差异仅能解释极微小的死亡率降低,前列腺特异性抗原筛查仍是死亡率降低的主要解释。

要点

  • 调整临床病理特征后,两组治疗分布差异为-3.3%至3.3%,远小于观察到的7.2%至10.1%。
  • 将对照组模型应用于筛查组,估计死亡数差异为0.05%(95%CI -0.1%至0.2%)。
  • 将筛查组模型应用于对照组,估计死亡数差异为-0.01%(95%CI -0.3%至0.2%)。

核心结论

  • 前列腺特异性抗原筛查仍是ERSPC试验中前列腺癌死亡率降低的主要解释,不能归因于试验组间的治疗差异。

研究设计与样本

  • 基于ERSPC试验中核心年龄组(55-69岁)随访16年的14 136例前列腺癌患者(筛查组7310例,对照组6826例)的分析。
  • 采用多分类逻辑回归模型调整中心、年龄、年份、前列腺特异性抗原、分级分组和肿瘤淋巴结转移分期,估计治疗分配。
  • 对每种治疗分别拟合逻辑回归模型评估前列腺癌死亡风险,比较观察与估计的死亡数。

主要发现

  • 两组观察与估计的治疗分布差异(激素治疗、根治性前列腺切除术、放疗和主动监测/等待观察)范围为-3.3%至3.3%。
  • 观察到的组间治疗分布差异范围为7.2%至10.1%。
  • 将对照组模型应用于筛查组(假设两组接受相同主要治疗),观察与估计的前列腺癌死亡数差异为0.05%(95%CI -0.1%至0.2%)。
  • 将筛查组模型应用于对照组,观察与估计的前列腺癌死亡数差异为-0.01%(95%CI -0.3%至0.2%)。
  • 观察到的组间差异为4.2%,治疗差异仅解释极微小部分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究仅可获得主要治疗的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Differential treatment between trial arms has been suggested to bias prostate cancer (PC) mortality in the European Randomized Study of Screening for Prostate Cancer (ERSPC). OBJECTIVE: To quantify the contribution of treatment differences to the observed PC mortality reduction between the screening arm (SA) and the control arm (CA). DESIGN, SETTING, AND PARTICIPANTS: A total of 14 136 men with PC (SA: 7310; CA: 6826) in the core age group (55-69yr) at 16yr of follow-up. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcomes measurements were observed and estimated numbers of PC deaths by treatment allocation in the SA and CA, respectively. Primary treatment allocation was modeled using multinomial logistic regression adjusting for center, age, year, prostate-specific antigen, grade group, and tumor-node-metastasis stage. For each treatment, logistic regression models were fitted for risk of PC death, separately for the SA and CA, and using the same covariates as for the treatment allocation model. Treatment probabilities were multiplied by estimated PC death risks for each treatment based on one arm, and then summed and compared with the observed number of deaths. RESULTS AND LIMITATIONS: The difference between the observed and estimated treatment distributions (hormonal therapy, radical prostatectomy, radiotherapy, and active surveillance/watchful waiting) in the two arms ranged from -3.3% to 3.3%. These figures, which represent the part of the treatment differences between arms that cannot be explained by clinicopathological differences, are small compared with the observed differences between arms that ranged between 7.2% and 10.1%. The difference between the observed and estimated numbers of PC deaths among men with PC was 0.05% (95% confidence interval [CI] -0.1%, 0.2%) when applying the CA model to the SA, had the two groups received identical primary treatment, given their clinical characteristics. When instead applying the SA model to the CA, the difference was, as expected, very similar-0.01% (95% CI -0.3%, 0.2%). Consistency of the results of the models demonstrates the robustness of the modeling approach. As the observed difference between trial arms was 4.2%, our findings suggest that differential treatment explains only a trivial proportion of the main findings of ERSPC. A limitation of the study is that only data on primary treatment were available. CONCLUSIONS: Use of prostate-specific antigen remains the predominant explanation for the reduction in PC mortality seen in the ERSPC trial and is not attributable to differential treatment between trial arms. PATIENT SUMMARY: This study shows that prostate cancer deaths in the European screening trial (European Randomized Study of Screening for Prostate Cancer) were prevented because men were diagnosed and treated earlier through prostate-specific antigen screening, and not because of different, or better, treatment in the screening arm compared with the control arm.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Carlsson SV, Månsson M, Moss S, et al. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer? Eur Urol. 2019. PMID: 30928162. doi:10.1016/j.eururo.2019.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。